FOLFOX + Bevacizumab

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-OXALIPLATIN` `DRUG-LEUCOVORIN` `DRUG-5-FLUOROURACIL` `DRUG-BEVACIZUMAB`

ID	`REG-FOLFOX-BEV`
Type	Regimen
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-COLON-2024` `SRC-NCCN-COLON-2025`

Notes

mCRC 1L for RAS-mutant patients (where anti-EGFR contraindicated) AND right-sided RAS-WT (CALGB-80405 — bev preferred over cetux for right-sided per ESMO 2024). Adds ~2-4 mo PFS over FOLFOX alone. Required pre-treatment: recent BP control, no recent surgery (≤28 d), no active hemorrhage, UPCR baseline.

Used By

Handbook Chapters

HB-CRC-METASTATIC-1L - Metastatic colorectal cancer: first-line biomarker reasoning

Indication

IND-CRC-METASTATIC-1L-FOLFOX-BEV - IND-CRC-METASTATIC-1L-FOLFOX-BEV
IND-CRC-OLIGOMET-LIVER-LIMITED - IND-CRC-OLIGOMET-LIVER-LIMITED